digipharm®
Home •  Site Map  •  Research  •  Reports  •  International Experts  •  Music Preparations  •  Fundamentals  •  News  •  Questions  •  Shop
digipharm®
peter huebner • micro music laboratories
M E D I C A L   R E S O N A N C E   T H E R A P Y   M U S I C®
R E D U C T I O N   O F   P S Y C H O – P H Y S I O L O G I C A L   M A N I F E S T A T I O N S   O F   S T R E S S

SCIENTIFIC RESEARCH

Research Fields Summary

Headaches

Migraine

Sleep Disorders

Pains

Neurodermatitis

Psoriasis

Medication Consumption

Dermatology

Dispersion of Stress

Faster Recovery

Mental Distress / Fear

Dizziness

Cardiovascular System

Hormone / Immune System

The Mental State

Operations

Radiation Sickness

ENT

Multiple Sclerosis

Gerontology

Diabetes

Cerebral & Nervous System

Mental & Sensory Abilities

Pediatrics

Pregnancy & Birth

Gynecology

Epilepsy

Concentration / Memory

Courage to Face Life

Creativity

Harmony

Mother & Child

Neurophysiological &
Sensory Disorders

Relaxation

Vital Energy

 

 






Scientific Studies and Clinical Observations
PREGNANCY & BIRTH
  • Faster normalization of excessively high blood pressure in pregnant women with mild OPH syndrome than in the medication group
  • Significant reduction in the number of premature births – from 14% down to 6,2% – since the introduction of treatment with Medical Resonance Therapy Music® for pregnant women facing the risk of miscarriage
  • Faster breakdown of the protein content in the urine of pregnant women with OPH syndrome
  • Significantly better development of the kariopicnotic index in pregnant women facing the risk of miscarriage than in the control group and, as a result, a significantly better pregnancy
  • Dispersion of the clinical risk characteristics in pregnant women with a threat of miscarriage:
    after 2-3 days there were no longer any clinical risk characteristics in 60% of the women, in 100% after 5-7 days. In the control group: the clinical risk characteristics had disappeared in 70% after 7-10 days, in 30% there was no complete dispersion of the risk characteristics
  • Improvement in the foetal heart activity in pregnant women with OPH syndrome: 20 – 30% faster than in the control group
  • Significant improvement in the hormone status in pregnant women with somatic disorders leading to a significant increase in the well-being of mother and child, compared to only minor improvement in the control group
  • Taking of foetal heart activity out of the danger zone to a very satisfactory condition
  • Calming of the child inside the mother’s body during labor
  • Improvement of uterine activity: increased strength and a more harmonic rhythm of uterine contractions in women with an initial inactivity of the uterus during labor.
  • Reduction of anxiety during labor.
  • Reduction of pain during labor.
  • Reduction of hormonal manifestations of stress during labor.
  • Improvement of the general mental state in women with a mild OPH-syndrome.
  • Improvement of restless and depressive states in pregnant women with a threatening loss of pregnancy: in 69,2% of the women a total normalization of the psychic state occurred, no woman showed an aggravation of these symptoms. The results of the control group: in 40% a complete normalization, in 40% a further aggravation of the state.
  • Improvement of the immune status of pregnant women diagnosed for a threatening miscarriage: after the treatment the percentage of healthy women was 55% versus 46% in the control group.
  • Faster recovery of pregnant women with an OPH-syndrom: by 14% faster than in the control group.
  • Reducing the frequency of headache attacks in pregnant women from 73% to 20%. In the control group an increase from 60% to 70%.
  • Improvement of sleep in 77% of the pregnant women with a mild form of the OPH syndrome.
  • Improvement of sleep in 77% of the pregnant women with a mild form of the OPH syndrome. Reducing the frequency of sleep disorders from 86% to 7%. In the control group an increase from 50% to 80%.
  • Reduction of psycho-emotional stress by 47% versus no reduction in the control group.
  • Almost complete elimination of the risk factor stress in pregnant women: reducing the stress hormone cortisol by 36% while at the same time doubling the hormone progesterone.
 


  For this indication please use the program:

PREGNANCY & BIRTH
 
 
 

   If you want to look at the studies in detail, please visit:

With kind permission of AAR EDITION INTERNATIONAL
© 1998-  DIGIPHARM >